Immunotherapy has been a primary area of focus in lymphoma research in recent years, with treatments looking to stimulate and bolster the patients immune system to figh cancer. In this interview, Raul Cordoba, MD, PhD, of Fundacion Jimenez Diaz University Hospital, Madrid, Spain, gives an overview of CAR T-cells and new monoclonal antibodies, two of the most relevant immunotherapies currently in development for treating lymphoma. This interview was recorded at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition, held in Atlanta, GA.
Immunotherapy discussions at ASH 2017
